Rituximab will be Manufactured in Kazakhstan
Cooperation with the Russian biotechnological company BIOCAD and Karaganda Pharmaceutical Complex (Kazakhstan) gives good fruit. The plan is to localize production of rituximab – a high-tech product based on monoclonal antibodies. The first stage of localization is already being implemented. Secondary packaging of finished substance supplied from Russia at production capacities of the Kazakhstan is to be performed. Deeper localization is planned. The Russian company will transfer its knowledge and experience in that area to its colleagues.
Dmitry Morozov, General Manager of BIOCAD told about signing a transfer agreement with the Karagada Pharmaceutical Complex (KPC), colleagues from Kazakhstan received production technologies of a number of biosimilars, including rituximab. Training of KPC personnel was performed, registration dossiers have been prepared. BIOCAD provided to Karaganda Complex the information about preclinical and clinical trials of drugs.
Soon manufacture of a rituximab biosimilar based on the pharmacological substance, will be launched in Kazakhstan. Rituximab manufactured at KPC will be an effective and more affordable alternative to the imported biosimilar. Kazakhstan may save costs on purchase of an important antineoplastic drug, insists Dmitriy Morozov. Manufacture of other biosimilars manufactured by BIOCAD by our colleagues from Karaganda will also affect the pricing. Two of them, trastuzumab and bevacizumab will be authorized in Kazakhstan next year.